NPC1L1 and sitosterolemia: If our observations in mice translate to phytosterolemia patients, then it will underscore the importance of raising awareness of this disorder, considering the issues surrounding misdiagnosis, the fact that statins are the first line standard of care therapy for hypercholesterolemia and are known to provide limited clinical benefit for phytosterolemia patients relative to the NPC1L1 inhibitor, ezetimibe36,41–44.